Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709288 | 1.00 | LRRK2 (0.31) | LRRK2GPR119 | |
| SCHEMBL707231 | 1.00 | LRRK2 (0.31) | LRRK2GPR119 | |
| SCHEMBL3826761 | 0.91 | GPR119 (0.31) | GPR119 | |
| SCHEMBL28756731 | 0.88 | CA1 (0.33) | — | |
| SCHEMBL707215 | 0.88 | CA1 (0.33) | — | |
| SCHEMBL224278 | 0.86 | CA1 (0.33) | — | |
| SCHEMBL9562903 | 0.81 | — | — | |
| SCHEMBL28718773 | 0.81 | — | — | |
| SCHEMBL28363128 | 0.79 | PDE4D (0.33) | — | |
| SCHEMBL26699713 | 0.79 | CA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12514859-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2026-01-06 | — | — | US | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1244645-B1 | STEREOSPECIFIC HYDROLYSIS OF OPTICALLY ACTIVE ESTERS | SIGMA TAU IND FARMACEUTI (IT) | 2004-08-25 | — | — | EP | disclosed |
| US-6593478-B2 | Preparing carnitine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-15 | — | — | US | disclosed |
| US-20030032818-A1 | Reacting a sulfonic, phosphoric, or phosphonic acid with an aqueous strong organic or inorganic acid at 60-100 degrees c | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | US | disclosed |
| EP-1244645-A1 | STEREOSPECIFIC HYDROLYSIS OF OPTICALLY ACTIVE ESTERS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047908-A1 | STEREOSPECIFIC HYDROLYSIS OF OPTICALLY ACTIVE ESTERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | LRRK2 3562/4885GPR119 1823/4885 |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | ITGB6, ITGB1, ITGA6 | LRRK2 1696/4885GPR119 1650/4885 |
| US-20030032818-A1 | Reacting a sulfonic, phosphoric, or phosphonic acid with an aqueous strong organic or inorganic acid at 60-100 degrees c | CPT1B, CPT1A, SLC25A20 | LRRK2 4816/4885GPR119 201/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | LRRK2 1100/4885GPR119 2624/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | LRRK2 132/4885GPR119 1654/4885 |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | LRRK2 278/4885GPR119 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.